Call for submissions – Current Oncology Special Issue on Real-World Evidence

Special Issue Information

Dear Colleagues,

Real-world evidence (RWE) has been a popular catchphrase for the last 10 years but could be considered the re-branding of clinical data that does not meet the typical randomized phase III study criteria often included in HTA submissions. Variations in patient populations (e.g., comorbidities, genetic mutations, etc.) especially in oncology are another reason why RWE is gaining prominence with its ability to address uncertainty and data gaps and is being accepted by decision-makers around the world. Furthermore, access and the use of cancer registries and linkages to administrative databases is flourishing, resulting in the demand for more clinical, quality of life and utility data outside the confines of a clinical trial and more representative of actual healthcare practices. However, there are still challenges being faced by RWE researchers, from privacy and legal restrictions to lack of consensus by regulatory bodies in terms of establishing RWE guidelines. Therefore, it is not surprising that the journal Current Oncology is preparing a Special Issue titled “The Role of Real World Evidence in Oncology: Opportunities, Results and Limitations” and I am privileged to be the guest editor. The goals are to publish original research in any oncology indication that uses real-world data to determine outcomes, promote and support young investigators with their research, and to highlight similarities and difference between regions and countries.


Soo Jin Seung
Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI’s English editing service prior to publication or during author revisions.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply